» Articles » PMID: 12437641

Anti-myeloma Activity of Natural Killer Lymphocytes

Overview
Journal Br J Haematol
Specialty Hematology
Date 2002 Nov 20
PMID 12437641
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Natural killer (NK) cells are assumed to contribute to a graft-versus-leukaemia effect. In vitro experiments have shown that many leukaemic cells are NK-cell sensitive. Nevertheless, no data concerning the influence of purified NK cells on malignant myeloma (MM) cells exist. We co-incubated NK cells with three different MM cell lines and fresh bone marrow samples of nine MM patients. The proportion of vital MM cells was determined before and after co-cultivation by a flow-cytometry-based assay. All MM cells tested, with the exception of one cell line (NCI H929), were susceptible to a NK-cell attack even without exogenous interleukin 2 (IL-2). The mean killing of the native MM samples was 23.1 +/- 5.4% and 34.5 +/- 6.5% at 10:1 and 20:1 effector:target ratio respectively, This corresponded to about 2/3 of those values obtained with the highly sensitive line K562. In contrast, CD34-positive haematopoietic stem cells as well as peripheral mononuclear cells were completely resistant under similar experimental conditions (1.3% killing). To elucidate the underlying triggering mechanisms, we measured human leucocyte antigen (HLA)-class I expression of the MM cells. No evidence for HLA loss, which could have explained the NK-cell recognition if it occurred, was demonstrated. These findings may contribute to the understanding of in vivo NK-cell activation and encourage clinical applications of NK cells for MM patients.

Citing Articles

Cellular Therapies for Multiple Myeloma: Engineering Hope.

Vera-Cruz S, Jornet Culubret M, Konetzki V, Alb M, Friedel S, Hudecek M Cancers (Basel). 2024; 16(22).

PMID: 39594822 PMC: 11592760. DOI: 10.3390/cancers16223867.


Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myeloma.

Tahri S, Piccinelli S, Su N, Lampe L, Dong H, Vergara Cadavid J Blood Adv. 2024; 8(20):5365-5370.

PMID: 39106432 PMC: 11568787. DOI: 10.1182/bloodadvances.2023010869.


Different evasion strategies in multiple myeloma.

Wang C, Wang W, Wang M, Deng J, Sun C, Hu Y Front Immunol. 2024; 15:1346211.

PMID: 38464531 PMC: 10920326. DOI: 10.3389/fimmu.2024.1346211.


NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells.

Petillo S, Sproviero E, Loconte L, Cuollo L, Zingoni A, Molfetta R Cell Death Dis. 2023; 14(7):438.

PMID: 37460534 PMC: 10352239. DOI: 10.1038/s41419-023-05949-z.


Adoptive Immunotherapy and High-Risk Myeloma.

Duane C, ODwyer M, Glavey S Cancers (Basel). 2023; 15(9).

PMID: 37174099 PMC: 10177276. DOI: 10.3390/cancers15092633.